Literature DB >> 21621301

[Hexaminolevulinate photodynamic diagnosis in non-muscle invasive bladder cancer: experience of the BLUE group].

J P Burgués1, G Conde, J Oliva, J M Abascal, I Iborra, M Puertas, F Ordoño.   

Abstract

OBJECTIVES: Photodynamic diagnosis (PDD) with hexaminolevulinate has been recently used to improve detection of non-muscle invasive bladder cancer. Our main purpose was to quantify the benefit of PDD vs. conventional white light cystoscopy (WL) in our area.
MATERIAL AND METHODS: Fluorescence-guided cystoscopy using hexaminolevulinate was performed at the time of the transurethral resection (TUR) in 305 patients from 7 Spanish hospitals. All lesions found with WL and PDD were numbered and recorded in an online database. Each lesion was sent separately for pathology analysis. Random biopsies were also obtained in 148 patients.
RESULTS: A total of 1659 lesions were biopsied: 522 were identified with PDD and WL, 237 only with PDD, 19 only with WL and 881 random biopsies. Of the 600 tumors, PDD detected 563, WL 441 and random biopsies 29 (20 CIS). The mean overdetection rate for PDD over WL was 31.9% for all types of lesions, but it was 209% for carcinoma in situ (CIS). Sensitivity was 93.8% for PDD and 78.2% for WL. Specificity was 81.5% for PDD and 90.5% for WL. In 23% of patients, PDD detected at least one additional neoplastic lesion compared to WL.
CONCLUSIONS: Hexaminolevulinate fluorescence cystoscopy improves detection and resection of non-muscle invasive bladder cancer, especially of CIS. Sensitivity of PDD is higher than WL, but specificity is lower. In our study, random biopsies were able to detect some CIS not visible under PDD.
Copyright © 2011 AEU. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21621301     DOI: 10.1016/j.acuro.2011.03.003

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  6 in total

Review 1.  Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder.

Authors:  Savino M Di Stasi; Francesco De Carlo; Vincenzo Pagliarulo; Francesco Masedu; Cristian Verri; Francesco Celestino; Claus Riedl
Journal:  Ther Adv Urol       Date:  2015-12

Review 2.  High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.

Authors:  Oscar Rodriguez Faba; Joan Palou; Alberto Breda; H Villavicencio
Journal:  World J Urol       Date:  2012-10-16       Impact factor: 4.226

Review 3.  Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.

Authors:  Lily P H Yang
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

Review 4.  Advances in Management of Bladder Cancer-The Role of Photodynamic Therapy.

Authors:  Tomasz Kubrak; Michał Karakuła; Marcin Czop; Aleksandra Kawczyk-Krupka; David Aebisher
Journal:  Molecules       Date:  2022-01-23       Impact factor: 4.411

5.  The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer - A New Analysis.

Authors:  Ashish M Kamat; Michael Cookson; J Alfred Witjes; Arnulf Stenzl; H Barton Grossman
Journal:  Bladder Cancer       Date:  2016-04-27

6.  Diagnostic performance of image technique based transurethral resection for non-muscle invasive bladder cancer: systematic review and diagnostic meta-analysis.

Authors:  Changhao Chen; Hao Huang; Yue Zhao; Hao Liu; Richard Sylvester; Tianxin Lin; Jian Huang
Journal:  BMJ Open       Date:  2019-10-17       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.